earnings
CL
NASDAQ · CLGN
CollPlant Biotechnologies Ltd.
Healthcare · Biotechnology
$3.48
Up+$0.08 (+2.35%)
Updated Sep 17, 2026, 11:44 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 23.78M
- P/E ratio
- -1.96
- Dividend yield
- 0.00%
- 52-week range
- $0.26 – $9.60
- Volume
- 105.66K
- Avg. volume
- 99.32K
Price performance
CLGN price history
1M range · 20 trading sessions · Daily adjusted prices
CLGN closed at $3.48 after 20 trading sessions, up 981.42% for the selected period.
- Last close
- $3.48
- Period change
- +981.42%
- Period low
- $0.29
- Period high
- $3.88
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $3.37 | $3.56 | $3.36 | $3.48 | 105.66K |
| Sep 15, 2026 | $3.51 | $3.55 | $3.38 | $3.40 | 67.9K |
| Sep 14, 2026 | $3.46 | $3.60 | $3.40 | $3.49 | 97.34K |
| Sep 11, 2026 | $3.56 | $3.70 | $3.37 | $3.50 | 126.9K |
| Sep 10, 2026 | $3.39 | $3.58 | $3.37 | $3.54 | 127.42K |
| Sep 9, 2026 | $3.51 | $3.57 | $3.30 | $3.41 | 91.06K |
| Sep 8, 2026 | $3.52 | $3.69 | $3.30 | $3.58 | 205.14K |
| Sep 4, 2026 | $3.31 | $3.91 | $2.99 | $3.55 | 237.69K |
| Sep 3, 2026 | $3.376 | $3.656 | $3.1001 | $3.412 | 209.46K |
| Sep 2, 2026 | $3.26 | $3.487 | $2.9115 | $3.433 | 287.38K |
| Sep 1, 2026 | $3.50 | $4.132 | $3.20 | $3.726 | 710.5K |
| Aug 31, 2026 | $3.80 | $9.60 | $3.61 | $3.879 | 18.27M |
| Aug 28, 2026 | $0.2891 | $0.4127 | $0.2637 | $0.358 | 8.98M |
| Aug 27, 2026 | $0.30 | $0.3079 | $0.28 | $0.2897 | 160.52K |
| Aug 26, 2026 | $0.30 | $0.3189 | $0.2905 | $0.3075 | 88.19K |
| Aug 25, 2026 | $0.33 | $0.33 | $0.2849 | $0.29 | 72K |
| Aug 24, 2026 | $0.33 | $0.33 | $0.3008 | $0.3008 | 142.3K |
| Aug 21, 2026 | $0.314 | $0.32 | $0.30 | $0.3125 | 30.87K |
| Aug 20, 2026 | $0.3078 | $0.3299 | $0.3002 | $0.3178 | 18.41K |
| Aug 19, 2026 | $0.3145 | $0.3249 | $0.3115 | $0.3218 | 16.43K |
Latest CLGN news
The latest Smart Investors Daily articles mentioning CLGN.
Stock researchResearch & News · Analysis
Loading stock research…

